41-year-old young woman, triglyceride is as high as 27, and taking routine blood lipid-lowering drugs is simply ineffective. What should this patient do? Is there nothing I can do about it?
This is a young hyperlipidemia patient I have seen recently. This type of hyperlipidemia patient is indeed a clinical problem and is also very representative. Today I will bring good news to these patients. People with high blood lipids, especially those with particularly high triglycerides, must read this article today. 
There are two types of hyperlipidemia patients in clinical practice, which is more troublesome to treat. The first category is the one that we mentioned at the beginning that is particularly high in triglycerides and has poor results in conventional drug treatment. The second category is the case where both triglycerides and cholesterol and are elevated. At this time, both triglycerides and cholesterol are generally elevated. These two types of patients are not easy to treat clinically and are also difficult to treat. The difficulty in treating the first type of situation is that it is difficult to reduce excessive triglycerides by oral medications, while the second situation is that it is likely that you need to take two drugs that reduce triglycerides and low-density lipoprotein at the same time, and liver function is more likely to be damaged.
So, the above situation is a difficult problem of high blood lipids, especially high triglycerides, and I am indeed looking forward to more effective treatment methods. Next, Dr. Zhang will introduce to you the new progress in this regard.
2 important and at the same time, taking aminotransferase is easier to increase
The good news is that a new drug can effectively treat this situation. This new drug is an antisense oligonucleotide preparation, and its English name is Vupanorsen. The mechanism by which this new drug can significantly reduce triglycerides and cholesterol is because it can control a key protein called ANGPTL3.
This protein , called "ANGPTL3", regulates it as the key protein for triglycerides and cholesterol metabolism of . Simply put, if it has strong functions and large quantities, the triglycerides and cholesterol levels will increase; if its functions are controlled, the triglycerides and cholesterol levels will decrease. What follows is the incidence of cardiovascular diseases such as myocardial infarction, cerebral infarction, , etc. Relevant data suggest that in people with loss-of-function mutations in ANGPTL3 and/or reduced plasma ANGPLT3 levels, the incidence of cardiovascular disease will be significantly reduced, and the risk of coronary heart disease is even reduced by 34%. Therefore, controlling the activity and quantity of this ANGPTL3 protein is the key to reducing triglycerides and low-density lipoprotein cholesterol. The new drug called Vupanorsen we mentioned is to control this protein and play a role.
At this stage, this new drug is in the Phase II clinical trial stage. If everything goes well, you will see that this new drug is used in clinical practice in about 2-3 years. We look forward to more good news. Everyone will follow the self-media account of Dr. Zhang Zhiying. I will report to you as soon as possible if I have good news later.
For more health knowledge in this area, you can click on the "Stay Away from Hyperlipids" column below to get it. The videos in the column are very valuable to patients with hyperlipids:
